Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 17, 2018

Primary Completion Date

November 30, 2030

Study Completion Date

November 30, 2030

Conditions
Sickle Cell Disease
Interventions
DRUG

Alemtuzumab, low dose total body irradiation, Sirolimus

"The conditioning regimen (SUN regimen) will consist of alemtuzumab daily for 5 days (total dose 1 mg/kg) and low dose total body irradiation (TBI) 300 cGY on Day -2 with gonadal shielding if possible. The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x106/kg recipient weight, goal of 10 x 106/kg (no upper limit). A peripheral blood stem cell (PBSC) graft was selected as it engrafts faster than bone marrow and would lead to shorter period of neutropenia and infection and less thrombocytopenia and need for platelet transfusion.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus will be continued at 1 mg/m2/day starting on day 0 and dose adjusted to maintain a target trough level 5-15 ng/mL for the first 3 months and 5-10 ng/mL for the remainder of the first year."

Trial Locations (7)

10032

RECRUITING

Columbia University, New York

20010

RECRUITING

Children's National Health System, Washington D.C.

28203

RECRUITING

Levine Children's Hospital, Charlotte

43205

RECRUITING

Nationwide Children's Hospital, Columbus

60611

RECRUITING

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

T3B 6A8

RECRUITING

Alberta Children's Hospital, Calgary

M5G 1X8

RECRUITING

The Hospital for Sick Children, Toronto

All Listed Sponsors
collaborator

Alberta Children's Hospital

OTHER

collaborator

The Hospital for Sick Children

OTHER

collaborator

Levine Children's Hospital

OTHER

collaborator

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER

collaborator

Nationwide Children's Hospital

OTHER

collaborator

The Children's Hospital at Montefiore

OTHER

collaborator

Columbia University

OTHER

lead

Robert Nickel

OTHER